Objective: To determine the effect on BCG of n-octanesulphonylacetamide (OSA), a novel compound of the class b-sulphonylcarboxamides, which has potent in vitro activity against pathogenic mycobacteria.
Introduction
Tuberculosis (TB) remains a significant health problem in the USA and globally. TB is the leading cause of death due to a single infectious agent in the world. Approximately 1.86 billion people or 32% of the world's population are infected with Mycobacterium tuberculosis.
1 There are about 8 million new active cases of TB per year and approximately 2 million deaths. 2 -5 This translates into a mortality rate of 200 people every hour and 5000 people every day. 3 Patients with HIV infection demonstrate a significantly increased susceptibility to M. tuberculosis with an $ 50-fold risk increase over patients without HIV. 6 -7 Similarly, the rate of progression of latent TB to active disease following initial infection is >40% compared with $ 5% in non-HIV-infected individuals. With the continued expansion of HIV globally, particularly in Asia and the Indian subcontinent, the incidence and mortality of TB can only be expected to increase. 2 In conjunction with the spreading epidemic of TB has been the emergence of drug resistance. 5,8 -10 Increasing incidence of M. tuberculosis strains resistant to one or more of the standard first-line agents intensifies the need for the identification of novel targets and new drug development. Multidrug-resistant (MDR)-TB is difficult and expensive to treat, as well as being associated with significantly higher mortality rates than drug-susceptible TB. 8, 11, 12 In the absence of effective prevention and therapeutic measures, MDR-TB will become an increasing and uncontrollable problem.
A significant need exists for improved TB drugs with reduced toxicity, activity against MDR-TB, alternative mechanisms of action and activity against latent disease. Several promising drug classes are under development including long-acting rifamycins, fluoroquinolones, 13 -15 oxazolidinones 16 and nitroimidazoles. 17 Given the success rate of new compounds coming to clinical use, $ 0.5%, there is a need for discovery and identification of new unique mycobacterial targets for development. No new antimycobacterial drugs with novel mechanisms of action have been developed in the past 30 years. n-Octanesulphonylacetamide (OSA) is a novel compound of the class b-sulphonylcarboxamides. As a class, these compounds have potent in vitro activity against pathogenic mycobacteria, including MDR-TB. 18, 19 b-Sulphonylcarboxamides were originally designed as inhibitors of the b-ketoacyl synthase step in fatty acid synthesis. However, earlier studies on the mechanism of action of OSA indicate that the highly specific, antimycobacterial activity of this b-sulphonylcarboxamide is not due primarily to fatty acid synthesis inhibition. 19 In this study we examined additional OSA-mediated effects in Mycobacterium bovis BCG using two-dimensional (2-D) gel electrophoretic protein profiles in response to various levels of OSA with concomitant sequencing of the overexpressed proteins and relevant biochemical assays. The OSA-mediated overexpression of two proteins, the b-subunit of ATP synthase (Rv1306) and hsp (Rv0251c) suggests a novel mechanism of action.
Materials and methods
Mycobacteria and culture conditions M. tuberculosis (H37Rv) and M. bovis BCG (BCG, Pasteur strain, ATCC 35734) were used in this study. Strains were maintained on Lowenstein -Jensen agar slants or Middlebrook 7H10 agar plates (Difco, Detroit, MI, USA). For all assays, M. bovis BCG cultures were grown at 378C in Middlebrook 7H9 -ADC-Tween broth (Difco) on a rotary shaker to mid-log phase (OD 600 0.3 -0.4).
Compounds
Stock and working solutions of OSA (Craig Townsend, Johns Hopkins University, Baltimore, MD, USA), dicyclohexylcarbodiimide (DCCD; an ATP synthase-specific inhibitor; ICN, Costa Mesa, CA, USA), thenoyltrifluoroacetone (TTFA; a respiratory complex II inhibitor; ICN), rotenone (a respiratory complex I inhibitor; ICN), dicumarol (an alternative dehydrogenase inhibitor; ICN) and cerulenin (a fatty acid synthase inhibitor; Sigma-Aldrich, St Louis, MO, USA) were made up in dimethyl sulphoxide (DMSO; Sigma). Stock solutions of isoniazid, streptomycin and ethambutol (all from Sigma) were prepared in sterile water. Initial stock solutions of rifampicin (Sigma) were made up in methanol with subsequent dilutions in sterile water.
Protein determinations
Protein assays were performed according to established protocols. Briefly, M. bovis BCG cultures were grown in Middlebrook 7H9-ADC -Tween broth to early log phase (OD 600 0.3-0.4). At this time, either DMSO (diluent), or OSA (MIC 6.25 mg/L; 16Â MIC 100 mg/L), cerulenin (24 mg/L), DCCD (15 mg/L) or isoniazid (1.0 mg/L) was added to 20 mL control and treated broth cultures, respectively. Following additional incubation for 24 h under the same conditions, cells were harvested by centrifugation (13 000 g for 30 s), the supernatant removed and the process repeated once using 1 Â PBS. The cellular contents of each tube were divided into two or three Eppendorfs ($ 3 -5 OD units per tube), and 250 mL of a lysis solution containing 3 M urea (Sigma), 0.5% Triton X-100 (Sigma), 500 mg dithiothreitol (DTT; Gibco BRL, Life Technologies, Gaithersburg, MD, USA) and 500 mL Pharmalyte (Pharmacia Biotech, Piscataway, NJ, USA) was added. Subsequently, phenylmethylsulphonyl fluoride (PMSF; Sigma) (100 mg/L) and leupeptin (2 mg/L) (Sigma) were also added. Mixtures containing cells and lysis solution were bead-beaten at maximum speed for 60 s in a Biospec Mini-8 beadbeater using 200-300 mm glass beads (Sigma). This process was repeated twice per sample with 30 s intervals on ice between agitations. The contents of each tube were centrifuged (13 000 g) for a minimum of 30 s and the protein-containing supernatant removed. Protein concentration was determined using a standardized colorimetric assay (Coomassie Plus; Pierce, Rockford, IL, USA) and BSA standards (Pierce) in a Shimadzu UC-1201 spectrophotometer. Quantified samples were aliquoted and frozen at À708C.
For time-course studies M. bovis BCG broth cultures (500 mL) were grown as described above (OD 600 0.3-0.4) and split into 150 mL aliquots and either DMSO or OSA (100 mg/L) was added to respective control and treated cultures followed by incubation and aeration at 378C for 1 h. Aliquots (20 mL) were removed from each culture at hourly intervals during the first 4 h after addition of compound, with extra time-points at 16, 24 and 48 h. Cells were harvested by low-speed centrifugation, washed once in sterile distilled water and frozen at À708C. For determination of protein synthesis BCG was grown at 378C, with shaking, to mid-log phase (OD 600 0.3 -0.4) and split into 150 mL aliquots. At this time, either DMSO, or OSA (100 mg/L), DCCD (100 mg/L) or TTFA (100 mg/L), respectively, were added to control and treated cultures as outlined above. Subsequently, 5.0 mCi/mL of [ 35 S]methionine was added to each culture followed by incubation at 378C. Aliquots (40 mL) were removed from each culture at 5 min, 1 and 3 h, the proteins extracted and quantified as described above. [ For 2-D gels and sequencing $ 250 mg of each protein sample was mixed with a solution containing 8 M urea, 0.5% Triton X-100, Pharmalyte 3-10, DTT and a few grains of Bromophenol Blue (Sigma) (240 mL total volume/sample). This mixture was used to rehydrate commercially prepared acrylamide pH strips (gradient 4 -7) overnight at room temperature using the manufacturer's standard protocols (Pharmacia Biotech). Completely rehydrated strips were subsequently subjected to a 2-D protein gel system according to standardized protocols (Pharmacia Biotech) [first dimension: 16 h at 208C, followed by equilibration of individual gel strips in a solution containing Tris -HCl (pH 6.8), urea (8 M), glycerol (30%) (Sigma), SDS (1 mg/mL) (Sigma) and either DTT or iodoacetamide (Sigma)]. Following equilibration, strips were applied to commercially prepared acrylamide gels (245 Â 110 Â 0.5 mm, gradient 8 -18%; Pharmacia) and run for 2 h at 158C following the manufacturer's standard protocols (Pharmacia). Molecular weight standards (size range: 14 -200 kDa) were purchased from Gibco BRL, Life Technologies and 10 mL loaded per gel. Proteins were visualized by Coomassie Blue (Sigma) staining of gels overnight. Excess stain was removed with two or three washes of methanol/water/acetic acid (9:9:2; Sigma). Proteins of interest from four gels were pooled and the excised gel fragments were washed twice in 50% acetonitrile. Subsequent protein sequencing analysis was performed at the Harvard Microchemistry Facility by microcapillary reversephase HPLC nano-electrospray tandem mass spectrometry (uLC/MS/MS) on a Finnigan LCQ DECA XP quadrupole ion trap mass spectrometer (Cambridge, MA, USA).
Reverse transcriptase -PCR
Total RNA was extracted with 1 mL of Trizol reagent (Invitrogen, Carlsbad, CA, USA) from 15 mL cultures of BCG treated for 15 min with either DMSO (diluent) or OSA (20 mg/L). Subsequently, bacterial cells were homogenized in a mini-beadbeater for 30 s (twice) and chloroform was added to the bacterial lysate. Total RNA was precipitated with iso-propanol, washed with ethanol and resuspended in distilled water (DNase, RNase free; Invitrogen). Total RNA (0.5-1.0 mg) was digested with two units of DNase I (Qiagen, Valencia, CA, USA) and purified with RNeasy mini-kit (Qiagen). Reverse transcription to cDNA was carried out according to the manufacturer's instructions using 2 mg of RNA and Super Script II, RNase H-reverse transcriptase (Invitrogen).
Forward and reverse primers were designed using MacVector software (Oxford Molecular Ltd, Oxford, UK) for the b-subunit of ATP synthase (atpF, Rv1306) and hsp (Rv0251c). They are as follows: atpF, 5 0 primer, 25185-GGATCCATGGGTGAAGGG-25202; 3 0 primer, 25700-CTGCAGTTACCTCGTCGC-25682; hsp, 5 0 primer, 15471-CGGTGGTCCGTTTGGAACTG-15490; 3 0 primer, 15191-CTTCGTGATGGCGATGCG-15172. Primers for the constitutively expressed control gene MT10Sa, which encodes a small, stable RNA, were made as described previously. 20 PCR amplification was performed in a Perkin Elmer 2400 thermal cycler. Each PCR contained 2 mL of cDNA, 2.5 mM MgCl, 0.2 mM dNTPs (Invitrogen) and 2.5 U of Taq polymerase (Invitrogen). Amplification parameters involved 30 cycles with 1 min at 958C, 1.5 min at 608C and 2 min at 728C. Elongation was carried out at 728C for 10 min. Subsequently, the temperature was set to 48C. Reaction products were evaluated by agarose gel electrophoresis.
PCR products were transferred onto nylon membranes (Roche Diagnostics, Indianapolis, IN, USA) by Southern blotting with 20Â SSC. Subsequently, individual membranes were hybridized with a gene-specific digoxigenin 11-dUTP (Dig)-labelled PCR fragment at 428C overnight. Probe was then removed and the membrane washed in both low-(2Â SSC, 0.1% SDS) and high-(0.5% SSC, 0.1% SDS) stringency buffer at room temperature and 688C for 15 min (twice), respectively. The Dig-labelled nucleic acid was detected using a commercially available chemiluminescence kit (Roche).
ATP assays
Either OSA at two concentrations (MIC 6.25 mg/L; 16Â MIC 100 mg/L) or diluent was added to 120 mL BCG cultures. Additional antimycobacterial agents were also tested at concentrations comparable to that used for OSA (16Â MIC in each case). These included isoniazid (1.6 mg/L), rifampicin (32 mg/L), streptomycin (32 mg/L), ethambutol (32 mg/L) and cerulenin (24 mg/L). Known respiratory chain inhibitors tested included DCCD (100 mg/L), an ATP synthase-specific inhibitor; TTFA (100 mg/L), a respiratory complex II-specific inhibitor; rotenone (25 mg/L), a respiratory complex I-specific inhibitor; and dicumarol (7 mg/L), an alternative dehydrogenase inhibitor.
The ATP level was determined using previously established methods by Colston and coworkers. 21 Briefly, single and multiple time-point assays were conducted by removing culture aliquots (30 mL) at 1, 3 and 24 h, and placing them immediately on ice. All subsequent manipulations were conducted at 48C. Additional time-courses were done at 5, 30 and 180 min using the same procedure. Cells were harvested by centrifugation and disrupted by bead-beating with 200-300 mm glass beads in an ATP extraction buffer (100 mM Tris, 4 mM EDTA, pH 7.5) at maximum force for a total of 2 min. Cellular debris was removed by centrifugation (13 000 g for 15 min), and the ATP-containing supernatant transferred to a clean tube. An ATP bioluminescence assay (Roche Diagnostics) was used to determine the ATP molar concentration (ATP[M]) in treated versus control samples. Relative light units were measured on a Wallac Victor luminometer.
Activity of OSA in the presence of ethanol
The in vitro activity of OSA in the presence of ethanol, a respiratory substrate, was determined using a modification of the standard Bactec radiometric growth procedure. 22 Briefly, inocula were prepared from M. bovis BCG and M. tuberculosis cultures maintained on Lowenstein -Jensen agar slants (Difco) using glass beads and commercially available diluting fluid (Becton Dickinson, Sparks, MD, USA). Mycobacterial suspensions were vortexed with glass beads and allowed to settle for 30 min. The supernatant was adjusted to a 1.0 McFarland standard and inoculated (0.1 mL) into each Bactec 12B bottle. OSA was added to individual bottles to the following final concentrations: 1.5, 3.0, 6.25, 12.5 and 25.0 mg/L. The final ethanol concentration in both controls and that used for combination testing was 2.3%. Combinations of streptomycin (0.05, 1.0 and 2.0 mg/L) and ethanol were also tested to determine whether synergic effects observed for OSA were compound specific or generalizable to an alternative antimycobacterial drug. All bottles were incubated at 378C, and the growth index of each bottle recorded daily.
Mycolic acid studies
BCG (50 mL) was grown aerobically at 378C in M7H9 -ADCTween to early log phase (OD 600 0.2). At this time, 1 mCi/mL of [1,2- 14 C]acetic acid (Amersham, Arlington Heights, IL, USA) and either diluent (DMSO), OSA (100 mg/L), DCCD (100 mg/L) or TTFA (100 mg/L), was added to the cultures and incubated under the same conditions for 10 min. Cultures were immediately placed on ice and cells were harvested by centrifugation at 3000 g for 15 min at 48C.
Mycolic acid extraction was performed as described previously. 20, 23 Briefly, polar and non-polar extractable lipids were removed from equal volumes of cells (60 mg wet weight) according to established protocols. The resulting defatted cells containing bound mycolic acids were subjected to alkaline hydrolysis in methanol (1 mL), 30% KOH (1 mL) and toluene (0.1 mL) at 758C overnight and subsequently cooled to room temperature. The mixture was then acidified to pH 1 with 3.6% HCl and extracted three times with diethyl ether. Combined extracts were dried under N 2 . Fatty acid methyl esters of mycolic acids were prepared by mixing dichloromethane (1 mL), a catalyst solution (1 mL) and iodomethane (25 mL), for 30 min, centrifuging and discarding the upper phase. The lower phase was dried under N 2 . Incorporation of [
14 C]acetate into mycolic acids was determined by scintillation counting (Beckman LS6500 multi-purpose scintillation counter) and values expressed as a percentage of untreated controls.
Results
Initially, the qualitative and quantitative biological effects of OSA were examined using 2-D gel electrophoretic protein profiles following 24 h exposure in BCG. Previous investigators successfully used a similar approach to determine the effects of isoniazid in M. tuberculosis. 24 As shown in Figure 1 (right), treatment with OSA resulted in significant overexpression of two relatively small proteins with approximate molecular weights of 17 -18 kDa. Both proteins were undetectable in the corresponding unexposed controls (Figure 1, left) . Expression of both proteins occurred at both the MIC of OSA (6.25 mg/L) and concentrations up to 16Â MIC (100 mg/L) in a dose-dependent manner (complete series of gels not shown). A separate timecourse experiment using [ 35 S]methionine pulse-labelling demonstrated that both proteins were expressed rapidly (4 h) post-OSA exposure. In contrast, treatment of BCG with cerulenin or isoniazid, two potent mycobacterial inhibitors, did not result in overexpression of either protein at concentrations of up to 16Â MIC. However, DCCD, an ATP synthase inhibitor, yielded a similar 2-D protein profile with two proteins consistent in molecular weight and pI with those present on the OSA gels (complete series of gels not shown).
Protein sequencing of pooled 2-D gel fragments containing each of the two proteins demonstrated the more prominent species (B in Figure 1 ) to be a small heat shock protein (hsp, Rv 0251c) of 17 786 Da with an isoelectric point (pI) of 5.0. The second protein (A in Figure 1 ) was identified as the b-subunit of ATP synthase encoded by the atpF gene (Rv1306), with a molecular weight of 18 325 Da and a pI of 4.9. In order to confirm the expression of AtpF and hsp visualized by 2-D protein electrophoresis, RT -PCR was performed on M. bovis BCG following a 15 min exposure to OSA (20 mg/L). MT10Sa, a small stable RNA, which is constitutively expressed at constant levels under a variety of stress conditions, was used as a control. As shown in Figure 2 , both atpF and hsp were actively transcribed following exposure to OSA compared with the control. Expression levels corresponded to the protein levels observed on the 2-D gels. There were no differences in expression of the MT10Sa control gene.
The global effect of OSA on protein synthesis was examined using pulse-labelling with [ ]methionine was markedly reduced at all three time-points examined. Subjectively, the decrease in protein synthesis was reflected in the 2-D gels. These decreases were 56%, 79% and 76% at 5 min, 1 h and 3 h, respectively. Protein synthesis was also inhibited following treatment of M. bovis BCG with the ATP synthase inhibitor DCCD and the complex II inhibitor TTFA at all three of the corresponding time-points. These decreases were 74%, 97% and 99% for DCCD and 77%, 73% and 57% for TTFA.
On the basis of the protein data, which suggested a possible connection to ATP synthase via interaction with the b-subunit, time-course studies over 24 h were performed to examine the effect of OSA (100 mg/L) on ATP levels in M. bovis BCG. As shown in Figure 4 , ATP[M] levels decreased rapidly (64%) in OSA-treated M. bovis BCG (P = 0.001) compared with unexposed controls at 5 min post-exposure. This was the earliest time-point for which we could obtain reproducible values using these methods. Following this initial rapid loss, a slight recovery occurred at 30 min (9%) and 1 h (17%), suggesting a compensatory mechanism for stabilization of the cellular ATP concentration. However, by 3 h cellular ATP concentration had declined to 44% and to 73% at 24 h when compared with unexposed controls.
To determine whether the rapid and dramatic decrease in cellular ATP observed following exposure to OSA could be the result of a generalized stress response in M. bovis BCG, a variety of respiratory chain inhibitors and antimycobacterial agents was evaluated. The respiratory chain inhibitors included rotenone, specific for NADH dehydrogenase (respiratory complex I); TTFA, a respiratory complex II inhibitor; DCCD, an ATP synthase-specific inhibitor; and dicumarol, an alternative dehydrogenase inhibitor. The remaining compounds evaluated included isoniazid, rifampicin, streptomycin, ethambutol and cerulenin, a fatty acid synthase inhibitor. The antimycobacterial agents were tested, as with OSA, at 16Â MIC. As shown in Figure 5 , isoniazid, dicumarol, rotenone, and cerulenin resulted in an increase in cellular ATP at 5 min post-exposure ranging from 1.9% for cerulenin to 20.7% for rotenone. In contrast, DCCD, TTFA, OSA, streptomycin, rifampicin and the combination of dicumarol and rotenone all resulted in a decrease in cellular ATP. The rapid loss of ATP demonstrated by OSA (63.7%, P < 0.001) was most closely mimicked by DCCD (92.4%, P < 0.001), the specific ATP synthase inhibitor.
Owing to the possible involvement of ATP synthase and other components of the respiratory chain, studies were performed with OSA in the presence of ethanol (2.3%). Ethanol is a respiratory substrate and has been used by several investigators to study cellular respiration. 25 -26 As shown in Figure 6 , 2.3% ethanol potentiated the effects of OSA on growth inhibition, reducing the MIC for M. bovis BCG from 6.25 to 3.0 mg/L. This potentiation was greater for M. tuberculosis H37Rv in which the MIC of OSA was reduced from 6.25 to < 1.5 mg/L (data not shown). No potentiation of activity was observed between ethanol and streptomycin (data not shown).
Previously we reported that treatment of M. bovis BCG with OSA resulted in a decrease in mycolic acids, with no apparent effect on intermediates in this pathway. 19 A significant decrease in available cellular ATP could potentially have direct or indirect deleterious effects on the biosynthesis of other macromolecules, including mycolic acids of the cell wall. To investigate the role of ATP synthesis and respiration in mycolic acid production, inhibitors of ATP synthase (DCCD) and respiratory complex II (TTFA) were evaluated and compared with OSA and unexposed controls in M. bovis BCG. A short time interval of 10 min post-exposure was selected to ensure that inhibition of mycolate synthesis was not due to cell death. As shown in Figure 7 , total mycolic acid levels decreased 79% with DCCD (100 mg/L), 46% with TTFA (100 mg/L) and 43% with OSA (100 mg/L) compared with untreated controls.
Discussion
In this study we further evaluated the effects of OSA in M. bovis BCG. Initial 2-D protein gel electrophoresis and subsequent sequencing of proteins demonstrated the overexpression of two relatively small proteins ($ 18 kDa): the b-subunit of ATP synthase (F 1 F 0 ATPase) encoded by the atpF gene and a small heat shock protein, hsp (Rv0251c). RT-PCR confirmed an increase in the level of hsp expression and to a lesser extent that of the b-subunit of ATP synthase, a pattern consistent with that observed on the 2-D gels. Initially, it was thought that overexpression of these two proteins could represent a generalized stress response to cell injury. To evaluate this possibility 2-D protein profiles were carried out in the presence of cerulenin, a potent antimycobacterial compound, 23 and isoniazid. Neither cerulenin nor isoniazid treatment resulted in overexpression of either protein in BCG. However, exposure to DCCD, an ATP synthase inhibitor, resulted in a similar protein profile, yielding overexpression of two proteins consistent in molecular weight and pI with AtpF and hsp.
Overexpression of the b-subunit of ATP synthase suggested the possible involvement of ATP synthase, whether direct or indirect, following exposure of M. bovis BCG to OSA. Based on these observations, single time-point and time-course experiments were undertaken to determine cellular ATP [M] in the presence of OSA compared with DCCD, a known ATP synthase inhibitor. ATP[M] decreased significantly following OSA and DCCD treatment at all time-points tested. This decrease was reproducible for both compounds and occurred very rapidly. To determine whether this effect was compound specific or the result of a generalized stress response, additional antimycobacterial drugs and inhibitors of respiration were tested for their ability to affect ATP[M] at corresponding time-points. No appreciable decrease in ATP [M] was detected at 5 min postexposure for any of the antibiotics or respiratory inhibitors tested, with the exception of TTFA, a specific inhibitor of complex II, which demonstrated a moderate decrease in ATP[M] at 5 min. This is not surprising since this inhibitor specifically targets succinate dehydrogenase (complex II), which is an integral part of the TCA cycle. Without this enzyme complex the TCA cycle is severely impaired. As a result, aerobic respiration becomes impaired, slowing the production of ATP.
In this study, OSA mimicked the effect of the well-documented ATP synthase inhibitor DCCD. In comparison, other antimycobacterial agents failed to elicit a similar effect. These findings suggest that OSA-mediated inhibition of ATP synthesis is specific in nature and not the result of cell death. These effects may involve direct or indirect interaction with the b-subunit of ATP synthase or other accessory or regulatory components of the complex. ATP synthases (F 1 F 0 ATPase) utilize energy from the proton motive force to generate ATP. This enzyme complex consists of transmembrane (F 0 ) and cytosolic (F 1 ) sectors.
The relative importance of the b-subunit to ATP synthase structure and function has been demonstrated by several laboratories. 27 -33 It has been suggested by several lines of investigation that the b-subunit may play a role in the coupling of proton translocation to catalysis. The b-subunit of F 0 would play both a structural and a functional role in the operation of F 1 F 0 ATPase. Inhibition of this complex could occur through direct interaction with the b-subunit or a membrane-associated component of F 0 , resulting in significant impairment of ATP generation. Alternatively, the OSA-mediated decrease in cellular ATP may involve currently unidentified regulatory components involved in energy production.
Mycobacterial regulation of ATP synthesis and energy production is poorly understood at this time. In this study, the OSAassociated decrease in ATP concentration was accompanied by overexpression of hsp (Rv0251c). This suggests the possibility that the heat shock response may be linked to energy sensing/ regulation in mycobacteria. This hypothesis is further strengthened by the similar response seen by 2-D protein profiles following DCCD treatment. Hsp (Rv0251c) encodes a relatively small protein of 159 amino acids and is a member of the Hsp20 or a-crystallin family of small heat shock proteins. Recently, Stewart et al. 34 demonstrated that hsp (termed acr2 by the authors) was the most heat-inducible gene in the mycobacterial genome. hsp is also arranged in an apparent operon with two adjacent genes (Rv0250c and Rv0249c). Regulation of hsp involves the heat shock repressor, HspR and an ECF sigma factor s E . 35 The latter is also up-regulated during oxidative or detergent stress 35 and bears similarity to the a-crystallin (acr) (14 kDa antigen) of M. tuberculosis (41% identity over 98 amino acids). The heat shock response is ubiquitous and allows cells to survive under both normal and deleterious stress conditions. Emerging evidence has identified the existence of enzymespecific chaperones, which are essential for the formation of specific enzyme complexes. Examples of enzyme-specific chaperones include the yeast ATP10, ATP11 and ATP12 genes, which encode proteins required for ATP synthase assembly. 36 Additionally, some molecular chaperones are subject to redox regulation. 37 The complete functional role of the mycobacterial hsp is largely unknown. However, the possibility exists that this heat shock protein may play a role in enzyme-specific assembly/regulation of ATP synthase or other associated complexes in the respiratory chain. Hsp may also represent a mycobacterial version of a redox-regulated heat shock protein. The potential of OSA-mediated interference in central energy metabolism was further strengthened by the potentiation of activity with ethanol. It is known that mycobacteria can utilize low concentrations of ethanol and other short chain alcohols as carbon sources. Ethanol is a respiratory substrate, which is reversibly oxidized to acetaldehyde with the concomitant reduction of NAD by alcohol dehydrogenase. 26 Subsequent oxidation of acetaldehyde yields acetic acid, which is then converted to acetylCoA in an ATP-dependent reaction. Acetyl-CoA is a critical molecule in central metabolism. Oxidation of acetyl-CoA via the TCA cycle drives the production of cellular energy. Thus, ethanol metabolism and respiration are interconnected. 25 Previous investigators have shown that ethanol increases the rate of ATP synthesis in mammalian mitochondria as a result of increased production of NADH + H + , which leads to elevated proton flux through the respiratory chain. ATP:O ratios increase following addition of ethanol, which indicates an increased energetic conversion between respiration and ATP synthesis. It is unlikely that ethanol and OSA share the same target. However, ethanol metabolism resulting in the generation of oxidized NAD in the absence of a functioning respiratory chain for its reduction would disrupt the essential NAD:NADH + H + ratios required for cellular metabolism. In such a case, potentiation of OSA and ethanol would be possible.
Inhibition of ATP synthesis and interference with cellular respiration could produce multiple downstream effects. These include a decrease in the energy-dependent synthesis of other macromolecules, such as mycolic acids and proteins. Previously, we reported that OSA decreased mycolic acid levels in M. bovis BCG, with no apparent effect on intermediates in this biosynthetic pathway. This observation was in contrast to the pattern of mycolate inhibition observed with thiolactomycin and cerulenin, known fatty acid synthase inhibitors. These findings suggested that inhibition of mycolic acid synthesis by OSA and other b-sulphonylcarboxamides could involve a mechanism other than fatty acid synthase inhibition. In this study, we demonstrated that inhibitors of ATP synthase and respiratory complex II could duplicate the effects of OSA on mycolic acid synthesis. Inhibition of energy production can result in a rapid non-specific decrease in mycolic acid synthesis. A similar effect could be expected on protein synthesis, which, as demonstrated in this study, decreased in parallel with ATP.
Conclusive identification of the target and mechanism of action of the b-sulphonylcarboxamides will answer these questions and provide a basis for rational, structure -function analysis, and guide the design and synthesis of new drugs for the treatment of TB.
